Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.
- Halfway recruitment milestone reached with 25 of 50 patients imaged
- Study expanded to second clinical site to accelerate enrolment
- Evaluating InVue for in vivo and InForm for ex vivo imaging
- Clinical data supports upcoming U.S. FDA submissions in H2 2026
- No adverse events reported and positive concordance with pathology
Milestone Reached in Breast Cancer Imaging Trial
Optiscan Imaging Ltd (ASX:OIL) has crossed the halfway recruitment mark in its inaugural human breast cancer imaging study, with 25 patients imaged out of a target 50 at The Royal Melbourne Hospital (RMH). The study, which began in June 2025, has now expanded to a second clinical site at Frances Perry House to boost recruitment speed.
This trial is critical for assessing Optiscan’s two flagship devices: the InVue® system, designed for real-time intraoperative imaging directly in the surgical cavity, and the InForm® platform, which analyses excised tissue ex vivo. The combination aims to enhance surgical margin assessment during lumpectomies, potentially reducing the need for repeat operations.
Promising Clinical Readouts and Workflow Integration
Clinical data from 18 analysed cases reveal a mix of clear, narrowly clear, and involved margins, with imaging results showing strong concordance against conventional histopathology. Both devices have demonstrated rapid image acquisition and ease of use, with no adverse events reported from the sodium fluorescein contrast agent used in vivo imaging.
The study is testing how these imaging technologies can be seamlessly integrated into surgical workflows, offering surgeons immediate, high-resolution visual feedback. This real-time insight could be a game-changer in breast-conserving surgery, a market projected to grow to nearly USD 4.6 billion by 2033 due to the high volume of breast cancer surgeries in the U.S.
Regulatory and Commercial Implications
Reaching this recruitment milestone is a key step toward Optiscan’s planned U.S. FDA submissions for both InVue® and InForm®, expected in the latter half of 2026. The data generated will underpin regulatory dossiers and support the company’s artificial intelligence and machine learning development efforts.
CEO Dr Camile Farah emphasised the study’s dual value: not only validating the clinical utility of the devices but also bolstering regulatory and commercial strategies. The company is positioning itself to capitalise on the growing demand for real-time imaging solutions in surgery and pathology, aiming for broader market adoption in the U.S.
Expert Endorsement and Next Steps
Professor Bruce Mann, lead investigator at RMH, highlighted the study’s potential to provide surgeons with immediate, detailed information during procedures, which currently remains limited. He noted that these technologies could reduce re-operative surgeries by improving intraoperative decision-making.
With the study now underway at two clinical sites and clinical readouts showing encouraging results, Optiscan is poised to maintain momentum toward regulatory approvals and commercial rollout. The next major catalyst will be the submission and subsequent review of FDA applications for both devices.
Bottom Line?
Optiscan’s progress in this breast cancer imaging study marks a crucial step toward FDA approval and U.S. market entry, but the commercial impact hinges on regulatory outcomes and broader clinical adoption.
Questions in the middle?
- Will the full study confirm the early concordance between Optiscan imaging and histopathology across a larger patient cohort?
- How will FDA regulators respond to the combined in vivo and ex vivo imaging approach in terms of approval timelines?
- What partnerships or commercial agreements might Optiscan pursue to accelerate U.S. market penetration post-approval?